Text Size

Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2007 by Nagoya University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Nagoya University
ClinicalTrials.gov Identifier:
NCT00408824
First received: December 6, 2006
Last updated: September 19, 2007
Last verified: September 2007
History of Changes
  Purpose

The metabolic syndrome is a highly prevalent disorder, which causes atherosclerotic cardiovascular disease and is closely associated with insulin resistance. The alteration of the secretion of adipocytokines from accumulated visceral adipose tissue in the obese induces insulin resistance. The purpose of this study is to identify gene polymorphisms that confer susceptibility to the metabolic syndrome and to make up a new health guidance program based on genetic risk assessment. About 25% of male employees over 45 years old in a certain company are diagnosed with the metabolic syndrome in medical examination. We, the researchers at Nagoya University, will analyze gene polymorphism and various biomarkers of over 3500 company employees.


Condition
Healthy
Metabolic Syndrome X
Hyperlipidemia
Hypertension
Diabetes Mellitus

Study Type: Observational
Study Design: Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective/Prospective
Official Title: Assessment of Genetic Risk of Metabolic Syndrome in Company Employee and Making New Health Guidance Program (NGK Study)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Nagoya University:

Estimated Enrollment: 4000
Study Start Date: September 2006
  Eligibility

Ages Eligible for Study:   20 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subjects who work for a certain company
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00408824

Contacts
Contact: Kenji Yasui, MD, PhD +81-52-788-6211 kenji@riem.nagoya-u.ac.jp

Locations
Japan
Department of Bio-information Analysis, Research Institute of Environmental Medicine, Nagoya University Recruiting
Nagoya, Aichi, Japan, 464-8601
Contact: Kenji Yasui, MD, PhD     +81-52-788-6211     kenji@riem.nagoya-u.ac.jp    
Principal Investigator: Kenji Yasui, MD, PhD            
Sponsors and Collaborators
Nagoya University
Investigators
Study Chair: Kenji Yasui, MD, PhD Department of Bio-information Analysis, Research Institute of Environmental Medicine, Nagoya University
  More Information

No publications provided by Nagoya University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00408824     History of Changes
Other Study ID Numbers: RIEM-G-3
Study First Received: December 6, 2006
Last Updated: September 19, 2007
Health Authority: Japan: Ministry of Education, Culture, Sports, Science and Technology

Keywords provided by Nagoya University:
insulin resistance
adipocytokine
Metabolic syndrome
Diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Hyperlipidemias
Hypertension
Metabolic Syndrome X
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
 Dyslipidemias
Lipid Metabolism Disorders
Vascular Diseases
Cardiovascular Diseases
Insulin Resistance
Hyperinsulinism

ClinicalTrials.gov processed this record on May 19, 2013